Adocia

Capital/Financing Update • Jan 9, 2018

PRESS RELEASE

Lyon, France, January 9, 2018 – 6 pm CET– Under the liquidity agreement entrusted by Adocia to Kepler Capital Markets, the following resources were listed on the liquidity account as at December 29, 2017:

• − 7,516 shares of Adocia and
• − 26,247.01 euros in cash.

At the last half year report dated June 30, 2017:

• − 6,671 shares of Adocia and
• − 31,267.6 euros in cash.

About ADOCIA

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia's portfolio of therapeutic proteins for the treatment of diabetes, featuring five clinical-stage products and four preclinical-stage products, is among the largest and most differentiated in the industry.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.

Adocia's clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone Combo). Adocia is also developing an aqueous formulation of human glucagon (BioChaperone Human Glucagon), two combinations of insulin glargine with GLP-1s (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide), two combinations of insulin lispro with synergistic prandial hormones (BioChaperone Lispro Pramlintide and BioChaperone Lispro Exenatide), and a concentrated, rapid-acting formulation of human insulin (HinsBet U500), all of which are in preclinical development.

Adocia aims to deliver "Innovative medicine for everyone, everywhere." To learn more about Adocia, please visit us at www.adocia.com

For more information please contact:

Adocia	Adocia Press Relations	Adocia Investor Relations
Gérard Soula	Europe	USA
Chairman and CEO	MC Services AG	The Ruth Group
contactinvestisseurs@adocia.com	Raimund Gabriel	Tram Bui
Ph. : +33 4 72 610 610	adocia@mc-services.eu	tbui@theruthgroup.com
	Ph. : +49 89 210 228 0	Ph.: +1 646 536 7035